Chromatographic Immunoassay Technology
Immunoassay technology, developed during the 1960s, relies on proteins called antibodies, which have the ability to recognize and bind to specific analytes called antigens. The first diagnostic tests based on immunoassay technology, such as the pregnancy test, were only capable of giving a qualitative, yes-or-no response. Qualitative immunoassay devices are small, simple to use, and capable of delivering rapid results.
Quantitative Assays and Handheld Instrumentation
Quantitative measurements are superior to qualitative assays as they provide more accurate information. Epinex has developed a series of immunodiagnostic assays in conjunction with a portable measuring instrument that will allow users to obtain immediate test results at the point of care. While some Epinex tests, such as ACR will rely on antibodies, the G1A test incorporates recent research that has extended the capabilities of immunoassay technology by using aptamers, artificially created proteins that act as powerful antibody markers. The Company is also exploring other technology extensions such as biosensors and microfluidics.
Rapid access to quantitative results will improve patient care and reduce overall health costs. The Epinex test system, based on its proprietary and intellectual property, is designed for ease of use in a doctor’s office, emergency room, ambulance or at the bedside.
Advantages of the Epinex Quantitative Immunoassay System for Point-of-Care Testing
Rapid: Results within minutes, not hours or days.
Quantitative: Yields a precise value, not just "yes" or "no".
Easy to use: No training required.
Cost effective: Point-of-care testing reduces the overall cost to the health care system.
High Sensitivity: Results comparable to the "gold standard" ELISA test.